Innovative startups 2013
Brady Huggett U S firms, particularly companies from the Boston area, continue to dominate Nature Biotechnology's listing of innovative startups, ranked in order of the 10 largest A rounds. This year's list is notable for the proportion of startups focusing on experimental gene therapies; indeed, firms developing adeno-associated virus (AAV) platforms garnered three of last year's largest A rounds. A familiar group of early stage funds participated in most of the financings in Table 1 , although the Children's Hospital of Philadelphia's decision to support a startup is notable. In total, the United States accounts for about two-thirds of firms receiving biotech A rounds in the broader life science field (Fig. 1) ; the United Kingdom ranks a very distant second. Although relatively few biotechs in France and Switzerland received A rounds, companies in those countries pulled in more on average than companies in the United States (Table 2) Number of A rounds A u s t r ia C a n a d a D e n m a r k F in la n d Ir e la n d S w e d e n Ic e la n d N o r w a y S w it z e r la n d T h e N e t h e r la n d s G e r m a n y F r a n c e U K U S 
